CRGX (Cargo Therapeutics) Total Current Assets : $410.02 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cargo Therapeutics's total current assets for the quarter that ended in Sep. 2024 was $410.02 Mil.

Cargo Therapeutics Total Current Assets Historical Data

The historical data trend for Cargo Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Total Current Assets Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Current Assets

0.18

3.93

409.48

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial						63.42	409.48	379.95	448.10	410.02

Cargo Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Cargo Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	405.732	+	1.739	+	0	+	2.006
	=	409.48

Cargo Therapeutics's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	404.848	+	2.872	+	0	+	2.2979999999999
	=	410.02

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Cargo Therapeutics (NAS:CRGX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Cargo Therapeutics's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	404.848	-	50.083	+	0.75 * 0	+	0.5 * 0
=	354.77

Cargo Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.